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Abstract
Background: Prior to routine screening of blood products many patients with haemophilia were infected
with hepatitis C virus (HCV) and have subsequently gone on to develop end-stage liver disease (ESLD).
Patients and Methods: We report our experience of liver transplantation (LT) in patients with haemo-
philia that developed ESLD secondary to HCV. Patients transplanted from 1994 to 2008 were identified
retrospectively. Patient demographics pre-, intra- and post-operative details and outcome were
documented.
Results: A total of 3800 LT were performed of which 13 had haemophilia A, 4 haemophilia B and one
factor (F)X deficiency. All patients were male with a median age of 52 years (range 26–59), all were HCV
antibody positive, 5 (28%) were human immunodeficiency virus (HIV) positive and 4 (22%) had hepato-
cellular carcinoma. Median intra-operative blood loss was 4.2 l (range 0.8–12) and all received coagula-
tion factor support peri-operatively. Coagulation was unsupported by 72 h post-operatively in all
recipients. Two patients developed complications as a result of post-operative bleeding. At a median
follow-up of 90 months, 8 patients have died, including 4 of the 5 patients that were HIV positive. The
median survival of patients with and without HIV co-infection was 26 and 118 months, respectively.
Conclusion: LT in patients with haemophilia cures the coagulation disorder and in the absence of
HIV/HCV co-infection is associated with long-term patient survival.
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Introduction
Up until the mid 1980s patients with haemophilia were treated by
replacing low levels of clotting factors with plasma pooled from
blood donors. Although effective for treating haemophilia the
majority of patients were exposed to hepatitis C virus (HCV) and
human immunodeficiency virus (HIV). By the time the health
risk was discovered an estimated 70% of patients treated with
pooled plasma had been infected with HIV and almost 100%were
positive for HCV.
Haemophilia patients infected with HCV appear to have a
higher risk of developing end-stage liver disease (ESLD) with a
cumulative risk of hepatic decompensation of 1.7% at 10 years
and 10.8% at 20 years. In the presence of HIV co-infection the
chance is even higher, with an estimated risk of 17% by 10
years.1–4 Consequently a large number of haemophilia patients
have gone on to develop ESLD. Liver transplantation (LT) is
established as the treatment of choice for patients with ESLD
secondary to HCV-related cirrhosis. In patients with haemo-
philia it also corrects the underlying haemostatic defect as both
factor (F)VIII and FIX are synthesized in the liver. Lewis et al.
reported the first successful LT in a patient with haemophilia
and ESLD.5 Despite initial concerns regarding LT in patients with
haemophilia, a number of small case series followed and
reported acceptable outcomes with patient survival at 1 and 3
years of 83% and 68%, respectively,.6 The introduction of highly
active anti-retroviral treatment (HAART) has significantly
improved the long-term outcome of HIV infection, although the
survival of HCV positive patients with haemophilia co-infected
with HIV appears to be significantly less.7 Recurrence of HCV
after LT is a problem common to all transplant recipients,
however, the presence of HIV co-infection is thought to enhance
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the replication of HCV leading to a more aggressive course
post-LT.8
The purpose of the present study was to review the outcome of
all patients with haemophilia, including those with HCV and HIV
co-infection, who underwent LT at King’s College Hospital.
Patients and methods
Patients
A prospective database of all patients undergoing LT at King’s
College Hospital has been maintained. The present study is based
on an analysis of the prospectively collected data and supple-
mented by review of clinical notes. From January 1994 to Decem-
ber 2008, a total of 3800 patients underwent LT, of which 18
(0.47%) had haemophilia and formed the basis of the present
study. All were male patients with a median age of 52 years (range
26–59). The severity of haemophilia was determined according to
the level of clotting factor. Severe was defined as a level <1%,
moderate 1–5% andmild 5–40% of normal. Thirteen patients had
FVIII deficiency (haemophilia A), of which seven were severe and
five mild (data not available for one patient). Four patients had
FIX deficiency (haemophilia B or Christmas disease), of which
two were severe and one was mild (data not available for one
patient). One patient had mild FX deficiency.
All patients were HCVRNA positive (Table 1). Genotype details
were available for 11 patients; 4 were genotype 3a, 3 were genotype
1, 2 were genotype 1a and 1 was genotype 1b. Eleven (61%)
patients received anti-HCV therapy pre-LT. Eight received non-
pegylated interferon monotherapy, and all were non-responders.
Three were treated with a combination of pegylated interferon
and ribavirin of which one was a non-responder and two
responded and relapsed within 6-months of completing therapy.
Five of the 18 (28%) patients had HIV co-infection (Table 2).
The mean duration of HIV infection prior to LT was 9.5 years
(range 5–14). The mean CD4+ T-lymphocyte count pre-LT was
228 cells/ml (range 160–297). HAART became available in 1995
and three patients were treated pre-LT and all recipients were
treated post-LT.
The pre-operative clinical details of all patients with haemo-
philia that underwent LT are summarized in Table 1. Four (22%)
had hepatocellular carcinoma (HCC), all of which were within
Milan criteria on pre-operative imaging and were treated with
doxorubicin-based (40 mg/m2) transarterial chemoembolization
prior to LT.
Protocol of clotting factors replacement
Haematologists were involved in the peri-operative management.
Pre-operative coagulation studies were performed, including
international normalized ratio (INR), activated partial thrombo-
plastin time (APTT) and fibrinogen level. Thromboelastography
(TEG) was used to monitor the coagulation profile intra-
operatively.Depending upon the type of haemophilia, FVIII, IX or
X levels were measured immediately prior to the LT, 12 and 24 h
Table 1 Pre-liver transplant clinical details
Patient
No
Age
(Years)
Haemophilia type Severity Co-aetiology HCV Albumin Bilirubin Creatinine INR MELD
scoreGenotype (g/l) (m mol/l) (m mol/l)
1 46 A Mild HCV 1a 27 45 86 1.55 15
2 26 A Sever HCV/HIV – 24 28 52 1.5 13
3 54 Factor X deficiency Mild HCV – 36 60 85 1.4 15
4 48 B Sever HCV – 17 56 114 1.9 21
5 36 A Sever HCV/HIV 1a 28 90 67 1.35 16
6 59 B unknown HCV – 36 25 105 1.24 12
7 34 A Mild HCV/HIV 1b 29 30 63 1.49 13
8 41 A Sever HCV – 22 597 238 1.8 36
9 57 B Sever HCV – 31 28 92 1.21 11
10 38 A unknown HCV – 26 31 63 1.7 15
11 41 A Sever HCV/HIV 1 38 13 75 1.02 7
12 56 B Mild HCV/HCC 1 39 22 72 1.28 10
13 58 A Mild HCV/HCC 3a 27 19 379 1.26 23
14 38 A Sever HCV/HIV 1 29 54 73 1.47 15
15 47 A Sever HCV/HCC 3 36 35 137 1.04 12
16 41 A Mild HCV 3a 25 39 107 1.25 14
17 51 A Mild HCV 3a 28 44 69 1.41 14
18 58 A Sever HCV/HCC 3a 27 53 70 1.25 13
HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; INR, international normalized ratio; MELD, model of
end-stage liver disease.
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post-LT, and thereafter daily until normal. Patients with FVIII
deficiency were administered FVIII pre-operatively, maintained
on an infusion intra-operatively (2 IU/kg/h) and post-operatively
(1 IU/kg/h) until the INR was <1.5. Patients with FIX deficiency
were administered FIX pre-operatively, intra-operatively and dis-
continued post-operatively once the level was >50 IU/l. Patients
with FX deficiency were managed according to our standard LT
coagulation protocol of fresh-frozen plasma (FFP) or cryoprecipi-
tate for fibrinogen deficiency and platelet concentrates to support
coagulation parameters.
Recurrent HCV
Recurrence of HCV in the allograft was diagnosed by the presence
of biochemical dysfunction in association with histological
changes on liver biopsy. Liver biopsies were performed in HCV-
positive patients to investigate graft dysfunction and since 1999
routinely at 12 months post-LT in all recipients.
Immunosuppression protocol
All patients received prednisolone tapered over 3 months and a
calcineurin inhibitor, either cyclosporine (n = 5) prior to 1997 or
tacrolimus (n = 13). The trough levels were maintained within
the range of 100–150 mg/l and 5–10 ng/ml, respectively. Rejec-
tion episodes were treated with three 1-g boluses of intravenous
methylprednisolone.
Statistical analysis
Data were entered into an electronic database and statistical analy-
sis performed using SAS version 9.1 (SAS Institute, Cary, NC,
USA). Descriptive statistics have been used to characterize the
study population. Time was measured from the date of LT to graft
loss, death or last follow-up. Patient and graft survival was calcu-
lated at 3 months, 1, 3 and 5 years post-LT using the Kaplan–Meier
method and compared with all adult (>16 years of age) recipients
transplanted over the same time period (n = 1593).
Results
Pre-LT patient demographics are summarized in Table 1. Sixteen
patients were transplanted with a whole liver, of which 14 were
from a deceased after brain death (DBD) donor and 2 were after
cardiac death. Two patients received a split right lobe DBD graft.
The median donor age was 33 years (range 14–73) with a median
intensive care unit (ICU) stay of 2 days (range 1–9). Median cold
and warm ischaemic times were 690 min (range 480–1050) and
38 min (30–58), respectively. Two donors were hepatitis B anti-
core antibody positive. The recipients of these grafts were hepatitis
B surface antigen negative and received long-term hepatitis B
immunoglobulin and lamivudine therapy post-transplant.
The median operative time was 300 min (range 270–450)
(Table 3). The median intra-operative blood loss was 4.2 l (range
0.8–12) with a median transfusion requirement of 6 units of
packed red cells (range 1–11) and 13 units of fresh frozen plasma
(FFP) (4–24). Fourteen patients required platelet transfusion with
a median of three bags (range 1–4) transfused per patient. Two
patients received two units of cryoprecipitate each.
All recipients had normal factor levels by 72 h post-LT. In
patients with haemophilia A the median FVIII level at 72 h
post-LT was 150 IU/dl (range 97–215). In patients with haemo-
philia B the median FIX level at 72 h post-LT was 148 IU/dl (range
104–236 IU/dl). The one patient with FX deficiency had a level of
125 IU/dl at 72 h post LT.
The post-operative outcome for all recipients is summarized in
Table 3. Of note, two patients had post-operative bleeding com-
Table 2 Demographic details of HIV-infected liver transplant recipients
Patient No Diagnosis of HIV
prior to LT (years)
CD4a count HIV viral loadb HAART
Pre- LT/Latest Pre-LT/Latest Pre-LT After LT
2 5 160/NA NA/NA No AZT
5 10 280/NA NA/NA No 3TC,AZT, SQV
7 14 260/47 965/NA 3TC,AZT, IDV 3TC,AZT, IDV
11 10 229/NA <50/NA d4T,TEN,3TC,EFV ddI,TEN,3TC,EFV
14 14 297/NA <50/<50 ABC,3TC,KAL,ddI SQV,KAL,truvada
aCD4 ¥ 106/l.
bViral load copies/ml.
LT, liver transplant; HAART, highly active anti-retroviral treatment; NA, not available; HIV, human immunodeficiency vírus; Drug abbreviations: 3TC,
lamivudine; AZT, zidovudine; IDV, indinavir; d4T, stavudine; TEN, tenofovir; EFV, efavirenz; SQV, saquinavir; KAL, kaletra; ddI, didanosine.
Table 3 Post-liver transplant clinical details
Median
(range)
Number
(%)
ICU stay (days) 2 (1–8)
Packed cell transfusion (units per patient) 6 (4–24)
FFP transfusion (units per patient) 13 (1–11)
Platelet transfusion (units per patient) 3 (1–4)
Postoperative bleeding 2 (11%)
Infectious complications 4 (22%)
Renal failure 3 (16%)
Acute cellular rejection 4 (22%)
HCV recurrence 11 (61%)
ICU, intensive care unit; FFP, fresh frozen plasma; HCV, hepatitis C virus.
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plications. One patient developed a retroperitoneal haematoma
with compression of the renal vein associated with renal dysfunc-
tion requiring laparotomy for control of bleeding day 2 post-LT.
Subsequently his renal function returned to normal and he made
an uneventful recovery. The second patient had a large subdural
haematoma.At the time of his subdural bleed, the FIX level and all
his clotting parameters were within the normal range. Surgical
evacuation of the clot was performed but the patient died day 12
post-LT. Eleven (61%) patients developed histological proven
HCV recurrence on liver biopsy at a median of 6 months (range
3–80) post-LT. Five of these patients remain alive; one patient
failed to respond to anti-HCV treatment and is currently being
considered for re-transplantation, two patients are currently
receiving anti-HCV treatment and the remaining 2 patients have
early signs of HCV recurrence and at the time of writing have not
been started on anti-HCV treatment.
The overall patient survival at 3 months, 1, 3 and 5 years
post-LT was 88.9%, 88.9%, 64.2%, and 53.5%, respectively
(Fig. 1). The 1-, 3- and 5-year survival for all other LT recipients
over the same period (n = 1593) was 86.0%, 80.9% and 77.5%,
respectively (Fig. 1). Of the 18 patients with haemophilia trans-
planted 8 died over a median follow-up period of 90 months
(range 12–184). Two died within the first year post-LT; one patient
with a subdural haematoma (described above), the other a patient
with HIV co-infection who developed fungal sepsis. The remain-
ing six deaths occurred after 12 months and were attributable to
HCV recurrence.
Four of the 5 HIV co-infected patients died resulting in a 1-
and 3-year survival for HIV co-infected patients of 81% and
60%, respectively (Fig. 2). One died at day 90 post-LT from
fungal sepsis (already described). The remaining 3 died as a
result of HCV recurrence at a medium of 30.5 months (range
16–46) post-LT. None of the HIV-positive patients developed
HIV-related complications.
All patients (n = 4) with a pre-operative diagnosis of HCC are
alive with no evidence of tumour recurrence at a median of 21
months (range 12–36) post-LT.
Discussion
The development of recombinant factor replacement
therapy has revolutionized the management of haemophilia.
Prior to its routine use pooled plasma was the only therapeutic
option and sadly many patients were infected with HCV and
HIV. These patients are now presenting with complications
of chronic liver disease. The results of this study demonstrate
that patients with decompensated liver disease and clotting
factor deficiency can be safely transplanted without excessive
transfusion requirement with acceptable long-term recipient
outcomes.
The success of LT in treating patients with haemophilia raises
the question whether prophylactic LT should be recommended as
a treatment for haemophilia. Although slight, the risk of
transfusion-related complications as a result of repeat blood
product administration and the possibility of developing compli-
cations of ESLD that preclude transplantation, such as advanced
HCC, are arguments that favour earlier transplantation. Against
this is the inherent morbidity and mortality associated with LT,
requirement for life-long immunosuppression and for many
re-infection of the graft with HCV that has a more aggressive
natural history. Gene therapy would be the ideal solution with
correction of the defective gene to enable for endogenous expres-
sion the deficient coagulation factor protein. To date, gene therapy
has proven difficult to transition into the clinic because of
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Figure 1 Recipient survival for patients with haemophilia after liver
transplantation (n = 18) compared with adult recipients transplanted
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inefficient protein production and dependency on retrovirus
vectors. Until gene therapy becomes a clinical reality LT remains
the only ‘cure’ for haemophilia. As a result of the inherent risks
associated with LT, haemophiliac patients with chronic liver
disease should be closely monitored and offered LT only when
they develop complications of chronic liver disease.
Recurrent HCV was the leading cause of graft loss in our series
and remains a persistent problem for all patients with HCV
undergoing LT. Attempts to prevent re-infection have not been
successful. In patients with compensated liver disease pre-
transplant treatment with pegylated interferon and ribavirin
therapy was shown in the HALT-C trial to result in a sustained
viral response (SVR) of only 11%.9 The treatment of individuals
with decompensated liver disease, who represent the majority of
potential transplant recipients, is even less encouraging. In our
series only 61% patients had sufficient hepatic reserve pre-
transplant to receive anti-HCV therapy pre-LT. Only two
responded and none developed a sustained virological response. It
has been observed previously that patients with haemophilia
respond poorly to interferon therapy which may account for a
higher proportion requiring LT than in the non-haemophilic
population.10 Both pre-emptive and directed therapies against
HCV have been attempted after transplant, with varying success as
a result of poor treatment tolerability. A randomized trial of pre-
emptive treatment with pegylated interferon and ribavirin showed
a SVR of only 8% with an early discontinuation rate of 31%.11–13 A
directed approach, only treating those with at least stage II fibro-
sis, resulted in a SVR of 7–26% and discontinuation rate of
between 30 and 50%.11–13 Because SVR is only achieved in a
minority of patients, modulating the severity of recurrent disease
to prevent graft loss remains the primary therapeutic goal. Unfor-
tunately for patients with haemophilia the rate of progression
appears to be more aggressive. Eleven (61%) of the patients in our
series developed histological changes of HCV-associated chronic
hepatitis at a median 6 months (3–80 months) post-LT. As a
comparison, in a longitudinal study of 149 patients reported by
Gane et al. from the same centre, 27% of patients transplanted for
HCV developed moderate chronic hepatitis at a median of 35
months and cirrhosis developed in 8% at a median of 51 months
post-LT.14 The possible viral, donor and recipient factors that
account for the more aggressive clinical course in patients with
haemophilia have not been identified.
It is well recognized that HIV accelerates the progression of
chronic liver disease in HCV co-infected patients. HCV-related
liver disease has become a major cause of death in HIV-infected
patients stabilized on HAART.15–20 The risk of hepatic decompen-
sation has been estimated to be 21-fold higher in HIV-positive
patients compared with HIV-negative patients.1 The mechanism
by which HIV results in higher rate of progression of HCV liver
disease remains speculative. Given that HIV does not appear to
cause hepatitis directly the effect is likely to be mediated by sup-
pression of the immune system against HCV. Supporting this,
HCV RNA levels tend to be higher in HIV-positive haemophilic
patients compared with those that are HIV negative.6 However, it
is not known whether the level of HCV RNA correlates with the
degree of liver injury and in a study of 26 co-infected haemophilia
patients they found no association between the stage of HIV infec-
tion and degree of fibrosis on liver biopsy.21 It has been postulated
that pharmacological interactions between calcineurin inhibitors,
the primary immunopressive used post-LT and protease
inhibitor-containing HAART regimens may explain the poor
outcome in co-infected patients. Pharmacokinetic interaction
between HAART and calcineurin inhibitors necessitates up to a
50-fold reduction in calcineurin inhibitor dosage.22,23 In our series
tacrolimus dose reductions were not observed prior to 2001. It is
possible that inadvertent over immuno-suppression in the three
patients transplanted before 2001 may have contributed to HCV
recurrence and poor outcome. There is also evidence that HCV
has a detrimental effect on the course of HIV infection. The Swiss
HIV Cohort study of over 3000 HIV positive patients on HAART
found that the relative risk of developing an AIDS-defining illness
or death in the co-infected group was 1.7 compared with HCV-
negative patients.24 None of the patients in our cohort have devel-
oped AIDS-defining illnesses.
Although the long-term outcome for patients that are HCV
positive and HIV negative is better than for patients who are
positive for both, all co-infected patients that have stable HIV
infection on or off HAART should be considered for LT. Prior to
the use of HAART the prognosis for patients with HIV infection
was poor. Gordon et al. reported 1- and 3-year survival in 6 HIV-
HCV co-infected hemophilic patients of 67% and 23%, respec-
tively, which was significantly worse than for the 19 HIV negative,
HCV positive patients (90% and 83%, respectively).7 With the
improvement in anti-retroviral therapy graft survival rates after
LT in HIV-positive patients has dramatically improved. A recent
retrospective review of 16 HIV-positive liver allograft recipients
(11 of which who were co-infected with HCV) from the USA
reported a 2-year actuarial survival of 80%.25 Many of the HIV-
positive patients in our cohort were transplanted before effective
anti-retroviral therapy was available which may explain the dif-
ference we observed in recipient survival.
In summary, LT can be safely performed in haemophilic patients
with acceptable peri-operative morbidity and mortality; however,
recurrence of HCV is common and our findings suggest that HIV
co-infection results in a more rapid and aggressive recurrence.
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